Technetium (99mTc) votumumab: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
No edit summary Tag: Manual revert |
| (One intermediate revision by the same user not shown) | |
(No difference)
| |
Latest revision as of 13:19, 18 March 2025
| Technetium (99mTc) votumumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | not marketed |
| CAS Number | 148189-70-2 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | |
Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.<ref>WHO Drug Information</ref> It was developed for the detection of colorectal tumors, but has never been marketed.<ref name="EMEA">EMA: Public Statement on HumaSPECT Archived 2007-06-10 at the Wayback Machine</ref>
The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.<ref>EMA: Summary of Product Characteristics for HumaSPECT</ref>
References[edit]
<references group="" responsive="1"></references>
| Diagnostic radiopharmaceuticals (V09) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
